| Nome |
# |
|
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis, file dd9e0c65-4484-1e9c-e053-3a05fe0a45ef
|
163
|
|
Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response, file dd9e0c69-5015-1e9c-e053-3a05fe0a45ef
|
163
|
|
Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myeloma–Enhanced Angiogenesis: A Novel Therapeutic Target?, file dd9e0c65-76fa-1e9c-e053-3a05fe0a45ef
|
73
|
|
Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma, file dd9e0c65-4f63-1e9c-e053-3a05fe0a45ef
|
69
|
|
Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing, file dd9e0c67-393e-1e9c-e053-3a05fe0a45ef
|
68
|
|
Identify multiple myeloma stem cells: Utopia?, file dd9e0c65-65a2-1e9c-e053-3a05fe0a45ef
|
66
|
|
Bone marrow endothelial cells sustain a tumor-specific CD8+ T cell subset with suppressive function in myeloma patients, file dd9e0c65-6639-1e9c-e053-3a05fe0a45ef
|
64
|
|
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial, file dd9e0c65-9414-1e9c-e053-3a05fe0a45ef
|
60
|
|
Heavy-chain diseases and myeloma-associated Fanconi syndrome: An update, file dd9e0c64-dfd6-1e9c-e053-3a05fe0a45ef
|
55
|
|
Functional interplay between NIK and c-Abl kinases limits response to Aurora inhibitors in multiple myeloma., file dd9e0c66-9b7b-1e9c-e053-3a05fe0a45ef
|
54
|
|
Angiogenesis and Antiangiogenesis in Multiple Myeloma, file dd9e0c68-29d1-1e9c-e053-3a05fe0a45ef
|
54
|
|
Extramedullary Plasmacytoma Mimicking Pancreatic Cancer: An Unusual Presentation, file dd9e0c63-e5e6-1e9c-e053-3a05fe0a45ef
|
51
|
|
Role of erythropoietin in the angiogenic activity of bone marrow endothelial cells of MGUS and multiple myeloma patients, file dd9e0c66-dd27-1e9c-e053-3a05fe0a45ef
|
51
|
|
Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma., file dd9e0c69-2e4a-1e9c-e053-3a05fe0a45ef
|
51
|
|
Different Adaptive Responses to Hypoxia in Normal and Multiple Myeloma Endothelial Cells, file dd9e0c65-48ff-1e9c-e053-3a05fe0a45ef
|
49
|
|
Suspected Pericardial Tuberculosis Revealed as an Amyloid Pericardial Mass, file dd9e0c65-6f92-1e9c-e053-3a05fe0a45ef
|
48
|
|
Filgrastim, lenograstim and pegfilgrastim in the mobilization of peripheral blood progenitor cells in patients with lymphoproliferative malignancies, file dd9e0c65-6da9-1e9c-e053-3a05fe0a45ef
|
45
|
|
Functional and biological role of endothelial precursor cells in tumour progression: A new potential therapeutic target in haematological malignancies, file dd9e0c63-e73b-1e9c-e053-3a05fe0a45ef
|
44
|
|
null, file dd9e0c65-659c-1e9c-e053-3a05fe0a45ef
|
44
|
|
A multiple myeloma that progressed as type i cryoglobulinemia with skin ulcers and foot necrosis: A case report, file dd9e0c65-66a8-1e9c-e053-3a05fe0a45ef
|
44
|
|
null, file dd9e0c69-0df5-1e9c-e053-3a05fe0a45ef
|
41
|
|
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials, file 1a03843b-1763-4fd3-9049-ce4aff88d151
|
38
|
|
High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment, file dd9e0c65-b63f-1e9c-e053-3a05fe0a45ef
|
35
|
|
Gene expression profiling of normal thyroid tissue from patients with thyroid carcinoma, file dd9e0c6b-5aec-1e9c-e053-3a05fe0a45ef
|
13
|
|
Halting prosurvival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes Bortezomid resistance in multiple myeloma patients., file dd9e0c64-c20e-1e9c-e053-3a05fe0a45ef
|
8
|
|
Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials, file dd9e0c6b-5ee1-1e9c-e053-3a05fe0a45ef
|
8
|
|
Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma, file dd9e0c65-0e30-1e9c-e053-3a05fe0a45ef
|
7
|
|
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: A randomised, multicentre, phase 3 trial, file dd9e0c65-659e-1e9c-e053-3a05fe0a45ef
|
5
|
|
Bone marrow stromal cells-induced drug resistance in multiple myeloma, file dd9e0c69-4e4f-1e9c-e053-3a05fe0a45ef
|
5
|
|
Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma, file dd9e0c63-0790-1e9c-e053-3a05fe0a45ef
|
4
|
|
Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients, file dd9e0c66-e512-1e9c-e053-3a05fe0a45ef
|
4
|
|
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis, file dd9e0c69-0df3-1e9c-e053-3a05fe0a45ef
|
3
|
|
Induction therapy and stem cell mobilization in patients with newly diagnosed multiple myeloma, file dd9e0c69-6457-1e9c-e053-3a05fe0a45ef
|
3
|
|
Echocardiographic findings and plasma endothelin-1 levels in obese patients with and without obstructive sleep apnea, file dd9e0c64-a97c-1e9c-e053-3a05fe0a45ef
|
2
|
|
Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia: a randomized trial, file dd9e0c65-4f5f-1e9c-e053-3a05fe0a45ef
|
2
|
|
Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20, file dd9e0c65-6667-1e9c-e053-3a05fe0a45ef
|
2
|
|
Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores the angiogenic homeostasis and suppresses tumor progression, file dd9e0c67-5222-1e9c-e053-3a05fe0a45ef
|
2
|
|
Effect of thyroidectomy on circulating angiogenic cytokines in papillary thyroid carcinoma and benign goiter: Potential for new biomarkers?, file dd9e0c68-3ed7-1e9c-e053-3a05fe0a45ef
|
2
|
|
Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients, file dd9e0c68-b680-1e9c-e053-3a05fe0a45ef
|
2
|
|
Right Heart Changes Impact on Clinical Phenotype of Amyloid Cardiac Involvement: A Single Centre Study, file dd9e0c68-b973-1e9c-e053-3a05fe0a45ef
|
2
|
|
Inhibition of endothelial and plasma cells NOTCH mediated comunication reduces angiogenesis in multiple myeloma patients., file dd9e0c69-10ac-1e9c-e053-3a05fe0a45ef
|
2
|
|
Bortezomib treatment modulates autophagy in multiple myeloma, file dd9e0c69-2111-1e9c-e053-3a05fe0a45ef
|
2
|
|
Short-Term Variations in Neutrophil-to-Lymphocyte and Urea-to-Creatinine Ratios Anticipate Intensive Care Unit Admission of COVID-19 Patients in the Emergency Department, file dd9e0c6a-5b60-1e9c-e053-3a05fe0a45ef
|
2
|
|
Prognostic and therapeutic role of angiogenic microenvironment in thyroid cancer, file dd9e0c6b-3ec4-1e9c-e053-3a05fe0a45ef
|
2
|
|
Imaging evaluation of pulmonary and non-ischaemic cardiovascular manifestations of covid-19, file dd9e0c6b-6656-1e9c-e053-3a05fe0a45ef
|
2
|
|
The bone marrow niche landscape: a journey through aging, extrinsic and intrinsic stressors in the haemopoietic milieu, file dd9e0c6b-cbd7-1e9c-e053-3a05fe0a45ef
|
2
|
|
Cardiovascular Risk in Patients With Takayasu Arteritis Directly Correlates With Diastolic Dysfunction and Inflammatory Cell Infiltration in the Vessel Wall: A Clinical, ex vivo and in vitro Analysis, file 3d8fca09-2545-4d2d-a566-669f604c2298
|
1
|
|
CORRELATION BETWEEN VASCULAR INFLAMMATION MARKERS, DIASTOLIC DYSFUNCTION AND CARDIOVASCULAR RISK IN PATIENTS WITH TAKAYASU ARTERITIS, file 5049c8c1-b655-4b87-95f1-45f4b6c4d025
|
1
|
|
Response to letter: "Effect of thyroidectomy on circulating angiogenic cytokines in papillary thyroid carcinoma and benign goiter: Potential for new biomarkers?", file d9ae21b8-d1d4-4509-9477-bb1642ed9de8
|
1
|
|
Is the efficacy of LDL apheresis in ischemic optic neuropathy linked to a reduction in endothelial activation markers?, file dd9e0c62-4a07-1e9c-e053-3a05fe0a45ef
|
1
|
|
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone(VMP) in untreated multiple myeloma patients with renal impairment., file dd9e0c62-852a-1e9c-e053-3a05fe0a45ef
|
1
|
|
"Real world" outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: Extended follow-up of a retrospective multicenter study by the "rete ematologica pugliese", file dd9e0c64-d7e6-1e9c-e053-3a05fe0a45ef
|
1
|
|
HIF-1a of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target, file dd9e0c65-0329-1e9c-e053-3a05fe0a45ef
|
1
|
|
Endothelial cells in the bone marrow of patients with multiple myeloma, file dd9e0c65-08ef-1e9c-e053-3a05fe0a45ef
|
1
|
|
Metronomic chemotherapy from rationale to clinical studies: A dream or reality?, file dd9e0c65-65a0-1e9c-e053-3a05fe0a45ef
|
1
|
|
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: Updated follow-up and improved survival, file dd9e0c65-65a7-1e9c-e053-3a05fe0a45ef
|
1
|
|
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials, file dd9e0c65-6662-1e9c-e053-3a05fe0a45ef
|
1
|
|
Efficacy and safety of once weekly bortezomib in multiple myeloma patients, file dd9e0c65-7d3f-1e9c-e053-3a05fe0a45ef
|
1
|
|
null, file dd9e0c66-fcfc-1e9c-e053-3a05fe0a45ef
|
1
|
|
Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study), file dd9e0c69-2b55-1e9c-e053-3a05fe0a45ef
|
1
|
|
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study, file dd9e0c69-39e2-1e9c-e053-3a05fe0a45ef
|
1
|
|
Involvement of NOTCH signaling in multiple myeloma angiogenesis and progression, file dd9e0c69-41f1-1e9c-e053-3a05fe0a45ef
|
1
|
|
null, file dd9e0c6a-07cc-1e9c-e053-3a05fe0a45ef
|
1
|
|
Inhibition of Notch-mediated crosstalk between endothelial cells and plasmacells reduces angiogenesis in multiple myeloma patients., file dd9e0c6a-f105-1e9c-e053-3a05fe0a45ef
|
1
|
|
Inhibition of Notch mediated communication in endothelial and plasma cells reduces angiogenesis in multiple myeloma patients., file dd9e0c6a-f703-1e9c-e053-3a05fe0a45ef
|
1
|
|
Adhesion-Mediated Multiple Myeloma (MM) Disease Progression: Junctional Adhesion Molecule a Enhances Angiogenesis and Multiple Myeloma Dissemination and Predicts Poor Survival, file dd9e0c6b-0f41-1e9c-e053-3a05fe0a45ef
|
1
|
|
Central Function for JAM-a in Multiple Myeloma Patients with Extramedullary Disease., file dd9e0c6b-0f44-1e9c-e053-3a05fe0a45ef
|
1
|
| Totale |
1.537 |